Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 3 1Phase 2 1

Status

Completed 5Unknown 1

Sponsor Class

INDUSTRY 5OTHER 3NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 2Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × INDUSTRY × genexol-PM × Clear all
NCT01023347 2017-05-09

A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer

Samyang Biopharmaceuticals Corporation

Phase 2 Completed
276 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00882973 2017-05-05

Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer

Samyang Biopharmaceuticals Corporation

Phase 1 Completed
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00876486 2017-05-01

Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer

Samyang Biopharmaceuticals Corporation

Phase 3 Completed
213 enrolled
Breast

Breast Neoplasms

NCT02064829 2016-03-25

TRIBECA

Sorrento Therapeutics, Inc.

Phase NA Completed
111 enrolled
Breast

Breast Neoplasms

NCT00877253 2012-06-12

Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer

Samyang Biopharmaceuticals Corporation

Phase 1 Completed
18 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡